Efficacy and tolerability of intravenous pentamidine isethionate for Pneumocystis jiroveci prophylaxis in a pediatric oncology population
The Pediatric infectious disease journal, ISSN: 1532-0987, Vol: 33, Issue: 3, Page: 319-321
2014
- 13Citations
- 23Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations13
- Citation Indexes12
- 12
- CrossRef11
- Clinical Citations1
- PubMed Guidelines1
- Captures23
- Readers23
- 23
- Mentions1
- News Mentions1
- News1
Most Recent News
Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia
STUDY INFORMATION OFFICIAL TITLE: Assessment of the Safety and Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia in Patients With Hematologic Malignancies and Stem Cell Transplant Recipients.
Article Description
Cancer therapy routinely requires Pneumocystis jiroveci prophylaxis. In those intolerant of trimethoprim/sulfamethoxazole, aerosolized pentamidine is convenient and effective. Intravenous pentamidine is often substituted in young children but its efficacy remains controversial. In this retrospective study of a large pediatric oncology cohort, we confirm intravenous pentamidine to be effective and well-tolerated as second-line prophylaxis across all ages.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85027947746&origin=inward; http://dx.doi.org/10.1097/inf.0000000000000044; http://www.ncbi.nlm.nih.gov/pubmed/24030353; https://journals.lww.com/00006454-201403000-00027; http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006454-201403000-00027; https://dx.doi.org/10.1097/inf.0000000000000044; https://journals.lww.com/pidj/Fulltext/2014/03000/Efficacy_And_Tolerability_of_Intravenous.27.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know